Apogee Licenses ABC294640 to RedHill Biopharma

Apogee has successfully licensed exclusive rights to ABC294640 to RedHill Biopharma.  Apogee looks forward to working closely with RedHill for late stage clinical development in many cancer and inflammatory indications. http://globenewswire.com/news-release/2015/03/31/720531/10126995/en/RedHill-Biopharma-Acquires-Phase-II-First-in-Class-Oral-Small-Molecule-SK2-Inhibitor-From-Apogee-Biotech.html